Efficacy of Cellex in patients with mild cognitive impairment

Background. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an ef...

Full description

Saved in:
Bibliographic Details
Main Authors: B. A. Abusueva, M. A. Evzel’man, P. R. Kamchatnov, Kh. Yu. Umarova
Format: Article
Language:Russian
Published: ABV-press 2019-04-01
Series:Нервно-мышечные болезни
Subjects:
Online Access:https://nmb.abvpress.ru/jour/article/view/167
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850025593652903936
author B. A. Abusueva
M. A. Evzel’man
P. R. Kamchatnov
Kh. Yu. Umarova
author_facet B. A. Abusueva
M. A. Evzel’man
P. R. Kamchatnov
Kh. Yu. Umarova
author_sort B. A. Abusueva
collection DOAJ
description Background. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an effective measure. MCI detection and timely initiation of treatment in most patients is essential to delay the onset of severe dementia.Objective. Investigating influence of Cellex in patients with chronic cerebral ischemia and MCI.Materials and methods. As a part of non-interventional observational comparative study we evaluated the results of Cellex administration in 90 patients with MCI. Patients were divided into 2 groups. Patients from both groups received 1 course of 10 subcutaneous injections of Cellex drug at the dose of 1 mL, and patients from group 2 received two identical courses with an interval of two months. The survey, which included psychometric testing by using special questionnaires (Mini-Mental State Examination, “Frontal Assessment Battery” and “Clock Drawing” tests, Schulte test) was performed before treatment, and at months 1 and 2 after its completion.Results. Neuropsychological examination revealed improvement in the patients state, more pronounced after the 2nd course of therapy.Discussion. Our results provide a basis for using Cellex in patients with chronic cerebral ischemia and MCI, allowing to proceede with further studies on the optimal dosage of that drug.
format Article
id doaj-art-be44d38e022243519de80f078cdb984e
institution DOAJ
issn 2222-8721
2413-0443
language Russian
publishDate 2019-04-01
publisher ABV-press
record_format Article
series Нервно-мышечные болезни
spelling doaj-art-be44d38e022243519de80f078cdb984e2025-08-20T03:00:46ZrusABV-pressНервно-мышечные болезни2222-87212413-04432019-04-0163172310.17650/2222-8721-2016-6-3-17-23145Efficacy of Cellex in patients with mild cognitive impairmentB. A. Abusueva0M. A. Evzel’man1P. R. Kamchatnov2Kh. Yu. Umarova3Dagestan State Medical Academy, Ministry of Health of RussiaI.S. Turgenev Oryol State University, Medical InstituteN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaMedical Faculty, Chechen State UniversityBackground. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an effective measure. MCI detection and timely initiation of treatment in most patients is essential to delay the onset of severe dementia.Objective. Investigating influence of Cellex in patients with chronic cerebral ischemia and MCI.Materials and methods. As a part of non-interventional observational comparative study we evaluated the results of Cellex administration in 90 patients with MCI. Patients were divided into 2 groups. Patients from both groups received 1 course of 10 subcutaneous injections of Cellex drug at the dose of 1 mL, and patients from group 2 received two identical courses with an interval of two months. The survey, which included psychometric testing by using special questionnaires (Mini-Mental State Examination, “Frontal Assessment Battery” and “Clock Drawing” tests, Schulte test) was performed before treatment, and at months 1 and 2 after its completion.Results. Neuropsychological examination revealed improvement in the patients state, more pronounced after the 2nd course of therapy.Discussion. Our results provide a basis for using Cellex in patients with chronic cerebral ischemia and MCI, allowing to proceede with further studies on the optimal dosage of that drug.https://nmb.abvpress.ru/jour/article/view/167chronic cerebral ischemiamild cognitive impairmentcellexneuropsychological testingcerebrovascular diseasedementia
spellingShingle B. A. Abusueva
M. A. Evzel’man
P. R. Kamchatnov
Kh. Yu. Umarova
Efficacy of Cellex in patients with mild cognitive impairment
Нервно-мышечные болезни
chronic cerebral ischemia
mild cognitive impairment
cellex
neuropsychological testing
cerebrovascular disease
dementia
title Efficacy of Cellex in patients with mild cognitive impairment
title_full Efficacy of Cellex in patients with mild cognitive impairment
title_fullStr Efficacy of Cellex in patients with mild cognitive impairment
title_full_unstemmed Efficacy of Cellex in patients with mild cognitive impairment
title_short Efficacy of Cellex in patients with mild cognitive impairment
title_sort efficacy of cellex in patients with mild cognitive impairment
topic chronic cerebral ischemia
mild cognitive impairment
cellex
neuropsychological testing
cerebrovascular disease
dementia
url https://nmb.abvpress.ru/jour/article/view/167
work_keys_str_mv AT baabusueva efficacyofcellexinpatientswithmildcognitiveimpairment
AT maevzelman efficacyofcellexinpatientswithmildcognitiveimpairment
AT prkamchatnov efficacyofcellexinpatientswithmildcognitiveimpairment
AT khyuumarova efficacyofcellexinpatientswithmildcognitiveimpairment